Healthcare / Drug Manufacturers - Specialty & GenericKSE
$15000.00
-710.00 (-4.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-21.2B · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$768.9B
P/E
87.2x
↑EV/EBITDA
34.5x
↑ROE
3.3%
↑Gross Margin
43.7%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
5.7%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $234.68B · net income $8.83B · FCF $13.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $234.68B | $234.68B | $221.09B | $200.23B | $209.29B |
| Net Income | $8.83B | $8.83B | $-15.39B | $-57.33B | $-35.38B |
| EBITDA | $22.53B | $22.53B | $-27.1M | $-39.81B | $-21.92B |
| EPS | 172.00 | 172.00 | -301.00 | -1119.00 | -691.00 |
| Gross Margin | 43.7% | 43.7% | 37.0% | 40.1% | 37.3% |
| Operating Margin | 6.1% | 6.1% | -7.7% | -23.7% | -16.3% |
| Net Margin | 3.8% | 3.8% | -7.0% | -28.6% | -16.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.21 | 0.17 | 0.01 |
| Current Ratio | 3.20 | 3.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.26B | $13.26B | $-21.24B | $-39.84B | $-32.67B |
| Returns | |||||
| ROE | 3.3% | 3.3% | -6.0% | -21.3% | -10.7% |
| Valuation | |||||
| P/E | 87.21 | 87.21 | — | — | — |
| EV/EBITDA | 34.53 | 34.53 | — | — | — |
| P/B | 2.85 | 2.85 | 3.22 | 3.99 | 6.66 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 10.4% | -4.3% | — |
| EPS Growth | 157.1% | 157.1% | 73.1% | -61.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
97.8%
EPS terminal req.
$1331.00
Spread vs growth
59.3%
5Y implied EPS CAGR
56.4%
EPS terminal req.
$1610.51
Spread vs growth
100.7%
10Y implied EPS CAGR
31.2%
EPS terminal req.
$2593.74
Spread vs growth
126.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-301.00 → 172.00
Residual
+20.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.